Dear editor,
We assessed clinical and cytogenetic responses to lenalidomide in nine transfusion-dependent patients with myelodysplastic syndrome (MDS) with deletion 5q (del5q) ( Table 1) . One patient was classified as RAEB-1, seven as RCMD and one as unclassified MDS. Six patients had low risk and three intermediate-1 risk according to the IPSS. BM samples were analysed by CC and by FISH every 6 months. All patients received lenalidomide 10 mg daily during 21 days each cycle, with adjustments according to tolerance.
Five of the patients had del5q with one additional chromosomal abnormality.
Reciprocal translocations are rare in MDS [1, 2] . Patient no. 2 had a primary t(6;11)(q21;q23) and acquired the del (5q), which supports a higher genetic instability. Deletion of MLL gene was excluded by FISH.
Individual studies suggested that a constitutional trisomy 8 mosaicism may be a first mutation in a multistep carcinogenic process [3] . Patient no. 4 had a constitutional trisomy 8, but after 91 months of follow-up without treatment no leukemic evolution has been observed. Patient no. 8 had an isolated trisomy 9 detected by CC, but due to high clinical and morphological suspicion of 5q minus syndrome FISH was performed, with 5q31 deletion being detected in 9% of the nuclei. We question as to whether treatment response depended of abolishing such a low 5q deleted cell burden.
Patients 3 and 4 interrupted treatment and have been followed for 17 and 19 months, respectively. All patients had persistent complete erythroid response and transfusion independence after a median of 17 months (6-26) of follow-up, including the ones who stopped treatment. Five patients achieved complete cytogenetic response, but two of them lost it after more than 24 months of treatment, without changes in Hb level. In these two cases, FISH studies performed 6 months before reappearance of del5q metaphases revealed ≥5% of 5q-cells.
Most published data of lenalidomide in MDS comes from multicentric trials. In our single centre series we confirm that patients with del5q are those who better respond to lenalidomide [4] . Since molecular methods to detect MRD are lacking, FISH has been studied as a more sensitive technique to predict response to lenalidomide [5] . Taking the cut-off of ≥5% of cells with del5q to consider FISH as positive, the results between CC and FISH were concordant in 88% of the studies. It is likely that a higher number of FISH 5q deleted cells can be found before reappearance of an abnormal karyotype during treatment with lenalidomide, but more cases are needed to establish whether FISH can or not predict the loss of cytogenetic complete response in treated patients.
With lenalidomide the quality of life of a mainly old population has been improved by avoiding transfusional side effects in del5q patients. Published data suggest that lenalidomide should be maintained until loss of erythroid or cytogenetic response or until intolerance [6] . However, authors showed that complete suppression of the del5q clone was not required for transfusion independence [7] . We have shown that patients that interrupt lenalidomide can sustain hematologic response even with the malignant clone in bone marrow, and that complete cytogenetic response can be lost during treatment without compromising the erythroid response. 
